INVESTORS.ARQULE.COM
Investor & Media | ArQule, Inc.The Investor Relations website contains information about ArQule, Inc.'s business for stockholders, potential investors, and financial analysts.
http://investors.arqule.com/
The Investor Relations website contains information about ArQule, Inc.'s business for stockholders, potential investors, and financial analysts.
http://investors.arqule.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Sunday
LOAD TIME
0.7 seconds
16x16
32x32
64x64
128x128
PAGES IN
THIS WEBSITE
15
SSL
EXTERNAL LINKS
20
SITE IP
23.213.123.49
LOAD TIME
0.704 sec
SCORE
6.2
Investor & Media | ArQule, Inc. | investors.arqule.com Reviews
https://investors.arqule.com
The Investor Relations website contains information about ArQule, Inc.'s business for stockholders, potential investors, and financial analysts.
investors.arqule.com
ArQule, Inc. | Financial Information
http://investors.arqule.com/financials.cfm
News & Events. Second Generation AKT Inhibition (ARQ 751). Rare Diseases Clinical Trials. Publications & Presentations. Investors & Media. Investor and Media FAQs. Investor and Media Contact. Second Quarter 2016 Financial Results. ArQule Reports Second Quarter 2016 Financial Results. File is in Briefcase. Q2 2016 ArQule, Inc. Earnings Conference Call. 2015 Annual Report on Form 10-K. File is in Briefcase. 2014 Annual Report on Form 10-K. File is in Briefcase. Apr 14, 2016. File is in Briefcase.
ArQule, Inc. | Stock Information
http://investors.arqule.com/stockquote.cfm
News & Events. Second Generation AKT Inhibition (ARQ 751). Rare Diseases Clinical Trials. Publications & Presentations. Investors & Media. Investor and Media FAQs. Investor and Media Contact. 001 ( 0.694%). 4:00 PM ET on Aug 26, 2016. Sign up for email alerts. Investor and Media FAQs. Investor and Media Contact. Please feel free to contact by one of the methods below. Rare Diseases Clinical Trials. Second Generation AKT Inhibition (ARQ 751). Investor and Media FAQs. Investor and Media Contact.
ArQule, Inc. | Press Releases
http://investors.arqule.com/releases.cfm
News & Events. Second Generation AKT Inhibition (ARQ 751). Rare Diseases Clinical Trials. Publications & Presentations. Investors & Media. Investor and Media FAQs. Investor and Media Contact. Aug 3, 2016. ArQule Reports Second Quarter 2016 Financial Results. File is in Briefcase. Jul 20, 2016. ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016. File is in Briefcase. Jul 18, 2016. Data supports further preclinical and clinical research in BTK sensitive and ibrutinib resistant maligna...
ArQule, Inc. | Briefcase
http://investors.arqule.com/briefcase.cfm
News & Events. Second Generation AKT Inhibition (ARQ 751). Rare Diseases Clinical Trials. Publications & Presentations. Investors & Media. Investor and Media FAQs. Investor and Media Contact. Collect, zip and download files from our Investor Relations website. Click on the briefcase icon. Located near most downloadable files throughout our IR website and use this page to manage your briefcase. You currently have no files in your Briefcase. Investor and Media FAQs. Investor and Media Contact.
ArQule and Beryllium Announce Collaborative Research and Development Agreement (NASDAQ:ARQL)
http://investors.arqule.com/releasedetail.cfm?ReleaseID=910812
May 5, 2015. File is in Briefcase. ArQule and Beryllium Announce Collaborative Research and Development Agreement. Parties to Focus on Immuno-Oncology Targets. Collaboration Provides for Target Screening Through Clinical Development and Commercialization of Priority Compounds. Agreement Leverages Applications of Beryllium Platforms to Validate Drug Targets and New Therapies. We are excited by the potential synergy in combining complementary technologies and expertise to pursue cost-effective, shared-risk...
TOTAL PAGES IN THIS WEBSITE
15
ArQule | Results from a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor, in Subjects with Advanced Solid Tumors or Recurrent Malignant Lymphoma
https://www.arqule.com/res
News & Events. BTK Inhibitor (ARQ 531). Rare Diseases Clinical Trials. Publications & Presentations. Investors & Media. Events & Presentations. Investor & Media FAQs. Investor & Media Contact. Results from a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor, in Subjects with Advanced Solid Tumors or Recurrent Malignant Lymphoma. Tuesday, September 1, 2015 Posters and Presentations. Please feel free to contact by one of the methods below. News & Events. Rare Diseases Clinical Trials.
ArQule | Contact
https://www.arqule.com/cont
News & Events. BTK Inhibitor (ARQ 531). Rare Diseases Clinical Trials. Publications & Presentations. Investors & Media. Events & Presentations. Investor & Media FAQs. Investor & Media Contact. Burlington, MA 01803. Senior Director, Investor Relations/Corporate Communications. Senior Director, Business Development and Alliance Management. Senior Director, Investor Relations/Corporate Communications. Senior Manager, Human Resources. News & Events. Please feel free to contact by one of the methods below.
ArQule | About
https://www.arqule.com/abo
News & Events. BTK Inhibitor (ARQ 531). Rare Diseases Clinical Trials. Publications & Presentations. Investors & Media. Events & Presentations. Investor & Media FAQs. Investor & Media Contact. Small Molecules for Precision Medicine. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. Is an oral selective and potent pan-AKT inhibitor that inhibits both wild-type and mutant AKT1, currently in development for onco...
TOTAL LINKS TO THIS WEBSITE
20
Aptar IR - Overview
Annual Report and Proxy. 160; 0.42. 07 Aug. 2015 4:00 pm ET. Minimum 15 minutes delay. Data Provided by Nasdaq. AptarGroup, Inc. is a leading global supplier of a broad range of innovative dispensing systems for the fragrance/cosmetic, personal care, pharmaceutical, household and food/beverage markets. AptarGroup is present in 20 different countries with manufacturing facilities in North America, Europe, Asia, and South America. Recent News View All. 28 Jul. 2015. AptarGroup Declares Quarterly Dividend.
Arc Logistics Partners LP - Investor Relations
We are a fee-based, growth-oriented limited partnership formed to own, operate, develop and acquire a diversified portfolio of complementary energy logistics assets. We are principally engaged in the terminalling, storage, throughput and transloading of crude oil and petroleum products. We are focused on growing our business through the optimization, organic development and acquisition of terminalling, storage, rail, pipeline and other energy logistics assets that generate stable cash flows. Aug 5, 2015.
Arista Networks - Company - Investors Relations - Investors Home
InvestorsHome span LayoutHomePageLayout Languageen-CA". Software Driven Cloud Networking. Software Driven Cloud Networking. View the 2014 Annual Report. Unsubscribe from Arista Networks email alerts. Director, Product and. Software Driven Cloud Networking. Aug 14, 2015 04:02 PM. Minimum 20 minute delay. Arista 2015 Q2 Highlights. Arista Networks, Inc. Reports Second Quarter 2015 Financial Results. August 6, 2015. Arista Networks to Announce Q2 Fiscal Year 2015 Financial Results on Thursday, August 6th.
investors.aristocratgroupcorp.com
Aristocrat Group Corp - Investors
ANNOUNCING BIG BOX VODKA. Yes, Vodka In A Box. 175 L Ultra-Premium Value Priced. SPiRIT INDUSTRY IS BOOMING. Simply put: We build and grow luxury spirit brands. We take a multi-channel approach to building a culture around products based on the spirit industry market. Our ability to identity, develops and launch trend spirit products and brands separate us from a single-brand investment opportunity. SIGN UP FOR E-MAIL ALERTS. ASCC Spirit Brand Driving Volume. Most Awarded American Vodka. And Shakes Up the.
Aritzia Inc - Investor Relations
Skip to main content. January 12, 2017. Aritzia is a rapidly growing, innovative design house and fashion retailer of exclusive brands. Board of Directors and Governance. Board of Directors and Governance. We conceive, create, develop and sell a strategic mix of women’s fashion products directly to our customers with a depth of design and quality that provides compelling value. Aritzia is listed on the Toronto Stock Exchange under the symbol "ATZ". Board of Directors and Governance. Sao Tome and Principe.
Investor & Media | ArQule, Inc.
Skip to main navigation. Rare Diseases Clinical Trials. Investor and Media FAQs. Investor and Media Contact. ArQule is led by a senior management team with significant clinical and commercial expertise that provides the leadership required to optimize its opportunities for success in a rapidly changing and highly competitive field. ArQule is listed on NASDAQ and trades under the ticker ARQL. Mar 20, 2018. ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018. Mar 15, 2018.
Ascent Solar - Investor Relations
Ascent Solar Technologies, Inc. (Nasdaq GM: ASTI. Jul 15, 2015. Investor Presentation, July 2015. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Ascent Solar's financial performance into perspective. Ascent Solar current Form 10-Q. May 15, 2015). Ascent Solar current Form 10-K/A. Mar 19, 2015). Jul 14, 2015. Jul 8, 2015. View all releases ». Aug 7, 2015. 12300 N. Grant St. Thornton, CO 80241.
investors.asia
The Sponsored Listings displayed above are served automatically by a third party. Neither the service provider nor the domain owner maintain any relationship with the advertisers. In case of trademark issues please contact the domain owner directly (contact information can be found in whois).
Investor Education Seminars Self Managed Super Fund Information - Australian Investors' Association » Australian Investors Association
Australia’s leading non-profit organisation providing assistance to its members to make improved investment decisions. A smorgasbord of ideas, education and strategies to consider as you make financial decisions to suit your own goals, skills, resources and risk profile. Opportunities to network with other members, many with considerable experience and success in investing. Our motto: Investors helping investors . NON MEMBERS - Sign up for our free "Investor Update" newsletter. And tell us whether you ag...
Aspire Investor Microsites | Log In
Thank you. We have sent a password to the email address specified. Please use this password to log in. A password has been created and sent to the specified email. The old password has been discontinued and will no longer allow access to this site. Please enter a valid email address below. We're sorry, but we couldn't find that email address on our list. We're sorry, but something went wrong. Please reload the page, and try again. Thank you. The email/password combination you entered is incorrect.
Investment property - buy to let property - investment properties - investment property for sale UK - buy to let estate agent
Search our Buy-to-let Properties. View All - Types. View All - Regions. Yorkshire and the Humber. Quick Register Why should I register? The Buy to Let Estate Agent. Assetz for Investors locates and pre-negotiates carefully selected investment-grade buy-to-let property. For private investors who wish to develop an investment business or portfolio. We offer a range of investment opportunities including new-build. And freehold property, along with a range of finance. The UK's Top Developments. I was really ...
SOCIAL ENGAGEMENT